non-small cell lung cancer

Research in Review

Novel Therapy Induces High Response Rate in Metastatic NSCLC

06/01/2017

JCP Editors

A novel antibody-drug conjugate is well tolerated and induces durable responses in pretreated patients with advanced non-small cell lung cancer (NSCLC), according to research published in the Journal of Clinical...

A...

06/01/2017

Journal of Clinical Pathways

Research in Review

Previous Radiotherapy Improves Response to Immunotherapy in NSCLC

05/30/2017

JCP Editors

Patients with advanced non-small cell lung cancer (NSCLC) who receive previous radiotherapy are more likely to benefit from immunotherapy than those patients without previous radiotherapy, according to research...

...

05/30/2017

Journal of Clinical Pathways

Research in Review

Targeted Therapy Improves Disease-Free Survival in Intermediate-Risk NSCLC

05/18/2017

JCP Editors

Adjuvant treatment with the targeted therapy gefitinib (Iressa, AstraZeneca) significantly improved disease-free survival (DFS) over standard of care after surgery for patients with non–small cell lung cancer...

...

05/18/2017

Journal of Clinical Pathways

Research in Review

Biomarker-Driven Treatment Does Not Improve NSCLC Outcomes

05/15/2017

JCP Editors

Selecting patients with cyclooxygenase-2 (COX-2) expression by immunohistochemistry fails to improve survival outcomes in non-small cell lung cancer (NSCLC), according to research published in the Journal of Clinical...

...

05/15/2017

Journal of Clinical Pathways

Research in Review

PD-1 Expression in T Cells Aids Immunotherapy Strategies for NSCLC

05/12/2017

JCP Editors

Early activation of programmed cell death-1 (PD-1) in CD8 T-cells after immunotherapy treatment is crucial to antitumor response for patients with non-small cell lung cancer (NSCLC), according to research published...

Early...

05/12/2017

Journal of Clinical Pathways

Research in Review

Patients With NSCLC Treated With Immunotherapy Likely to Respond to Chemo

05/09/2017

JCP Editors

Patients with advanced non-small cell lung cancer (NSCLC) who undergo salvage chemotherapy are 30% more likely to achieve partial response if they have been treated with a PD-1/PD-L1 checkpoint inhibitor, according...

...

05/09/2017

Journal of Clinical Pathways

Research in Review

New Biomarker Helps Predict PFS in Patients With Type of NSCLC

05/05/2017

JCP Editors

Patients with ALK-rearranged non-small cell lung cancer (NSCLC) who are treated with crizotinib may experience increased progression-free survival (PFS) with a decrease in a type of circulating tumor cells, according...

...

05/05/2017

Journal of Clinical Pathways

Research in Review

PD-1 Expression in T-Cells Aids Immunotherapy Strategies for NSCLC

05/01/2017

JCP Editors

Early activation of programmed cell death-1 (PD-1) in CD8 T-cells after immunotherapy treatment is crucial to anti-tumor response for patients with non-small cell lung cancer (NSCLC), according to research published...

Early...

05/01/2017

Journal of Clinical Pathways

Department

Cost-Effectiveness Analysis Reveals Optimal Immunotherapy for Metastatic NSCLC

04/12/2017

JCP Editors

Recent research suggests a particular immunotherapy may be less costly and offer time savings compared with nivolumab for patients with metastatic non-small cell lung cancer (NSCLC). Immune checkpoint inhibitors,...

Recent...

04/12/2017

Journal of Clinical Pathways

Research in Review

New Drug Improves PFS for Patients With ALK-Positive NSCLC

04/10/2017

JCP Editors

Patients with anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC) live significantly longer without disease progression when treated with a new drug compared with those treated with...

...

04/10/2017

Journal of Clinical Pathways